全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用:99美元

查看量下载量

相关文章

更多...
华西医学  2015 

Toll样受体7激动剂刺激肾癌患者外周血单个核细胞中免疫相关因子表达的实验研究

DOI: 10.7507/1002-0179.20150580, PP. 2035-2039

Keywords: 肾癌,Toll样受体7,Gardiquimod,免疫相关因子

Full-Text   Cite this paper   Add to My Lib

Abstract:

目的?研究肾癌患者中Toll样受体7(TLR7)活化后免疫相关因子的表达变化。方法?2013年6月分离1例肾癌患者外周血单个核细胞(PBMC)并用TLR7特异激动剂Gardiquimod刺激4h后,用定量聚合酶链式反应方法检测多个免疫相关因子的表达变化。结果?TLR7刺激PBMC后,多个免疫相关因子的表达明显受影响,其中黏附因子的表达均被抑制,多个细胞因子、白细胞介素类因子和趋化因子的表达被明显诱导。结论?TLR7通路活化后可明显增强PBMC中炎症相关因子的表达,具有潜在的临床治疗价值。

References

[1]  11 那彦群, 叶章群, 孙颖浩, 等. 中国泌尿外科疾病诊断治疗指 南[M]. 北京: 人民卫生出版社, 2013.
[2]  12 Delahunt B, Eble JN, Mccredie MR, et al. Morphologic typing of papillary renal cell carcinoma: comparison of growth kinetics and patient survival in 66 cases[J]. Hum Pathol, 2001, 32(6): 590-595.
[3]  13 Palapattu GS, Kristo B, Rajfer J. Paraneoplastic syndromes in urologic malignancy: the many faces of renal cell carcinoma[J]. Rev Urol, 2002, 4(4): 163-170.
[4]  14 张卫民, 何廉波. 肾癌治疗的研究进展[J]. 河北医学, 2009, 15(9): 1122-1123.
[5]  15 Rosenberg SA. Gene therapy for cancer[J]. JAMA, 1992, 268(17): 2416-2419.
[6]  16 Shiba M, Nonomura N, Nakai Y, et al. Type-Ⅰinterferon receptor expression: its circadian rhythm and downregulation after interferon-alpha administration in peripheral blood cells from renal cancer patients[J]. Int J Urol, 2009, 16(4): 356-359.
[7]  17 Gery I, Gershon RK, Waksman BH. Potentiation of the T-lymphocyte response to mitogens. I. The responding cell[J]. J Exp Med, 1972, 136(1): 128-142.
[8]  1 Sugawara E, Togashi Y, Kuroda N, et al. Identification of anaplastic lymphoma kinase fusions in renal cancer: large-scale immunohistochemical screening by the intercalated antibody-enhanced polymer method[J]. Cancer, 2012, 118(18): 4427-4436.
[9]  2 Nepple KG, Yang L, Grubb RL, et al. Population based analysis of the increasing incidence of kidney cancer in the United States: evaluation of age specific trends from 1975 to 2006[J]. J Urol, 2012, 187(1): 32-38.
[10]  3 Cohen HT, Mcgovern FJ. Renal-cell carcinoma[J]. N Eng J Med, 2005, 13(2): 2477-2490.
[11]  4 仉洁, 钟理, 石伟, 等. 肾细胞癌免疫治疗的研究进展[J]. 中国肿瘤生物治疗杂志, 2013, 20(1): 120-123.
[12]  5 Miyake K. Innate immune sensing of pathogens and danger signals by cell surface Toll-like receptors[J]. Semin Immunol, 2007, 19(1): 3-10.
[13]  6 Kopp E, Medzhitov R. Recognition of microbial infection by Toll-like receptors[J]. Curr Opin Immunol, 2003, 15 (4): 396-401.
[14]  7 Sch?n MP, Sch?n M. TLR7 and TLR8 as targets in cancer therapy[J]. Oncogene, 2008, 27(2): 190-199.
[15]  8 Ghosh TK, Mickelson DJ, Solberg JC, et al. TLR-TLR cross talk in human PBMC resulting in synergistic and antagonistic regulation of type-1 and 2 interferons, IL-12 and TNF-alpha[J]. Int Immunopharmacol, 2007, 7(8): 1111-1121.
[16]  9 马建辉. 晚期肾癌靶向治疗临床研究现状[J]. 实用肿瘤杂志, 2010, 25(3): 257-260.
[17]  10 张永贞, 杨国庆, 王新正, 等. 2003~2007年中国肾及泌尿系统其他癌发病分析[J]. 中国肿瘤, 2012, 21(8): 561-565.
[18]  18 Montagna D, Turin I, Schiavo R, et al. Feasibility and safety of adoptive immunotherapy with ex vivo-generated autologous, cytotoxic T lymphocytes in patients with solid tumor[J]. Cytotherapy, 2012, 14(1): 80-90.
[19]  19 Dillman RO. Cancer immunotherapy[J]. Cancer Biother Radiopharm, 2011, 26(1): 1-64.
[20]  20 Galanis E, Burch PA, Richardson RL, et al. Intratumoral administration of a 1, 2-dimyristyloxypropyl-3- dimethylhydroxyethyl ammonium bromide/ dioleoylphosphatidylethanolamine formulation of the human interleukin-2 gene in the treatment of metastatic renal cell carcinoma[J]. Cancer, 2004, 101(11): 2557-2566.
[21]  21 孙飞达, 王东文, 米振国. 肾癌分子靶向治疗的现状及研究进 展[J]. 现代泌尿生殖肿瘤杂志, 2012, 4(1): 1-3.
[22]  22 Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors[J]. Nat Immunol, 2010, 11(5): 373-384.
[23]  23 Kaisho T, Akira S. Toll-like receptor function and signaling[J]. J Allergy Clin Immunol, 2006, 117(5): 979-987; quiz 988.
[24]  24 Smits EL, Cools N, Lion E, et al. The Toll-like receptor 7/8 agonist resiquimod greatly increases the immunostimulatory capacity of human acute myeloid leukemia cells[J]. Cancer Immunol Immunother, 2010, 59(1): 35-46.

Full-Text

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133